ARATANA THERAPEUTICS, INC.
ARATANA THERAPEUTICS, INC. (PETX): 6 pipeline candidates · ~23 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
23.1 months
D/E 0.09 · 0% dilution
Lead: Approved
6 candidates
N/A
N/A
A transparent, data-derived signal for ARATANA THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$36.9M
Quarterly Burn
$5.5M
Runway
23.1 mo
Revenue
$7.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| at-003 | Preclinical |
| at-019 | Preclinical |
| canine osteosarcoma vaccine | Approved |
| entyce | Approved |
| galliprant | Approved |
| nocita | Approved |
Frequently asked questions
How many drug candidates are in ARATANA THERAPEUTICS, INC.'s pipeline?
ARATANA THERAPEUTICS, INC. (PETX) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ARATANA THERAPEUTICS, INC.'s lead drug candidate?
ARATANA THERAPEUTICS, INC.'s most advanced tracked candidate is at-003 (Preclinical) for post-operative pain in cats.
What is ARATANA THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ARATANA THERAPEUTICS, INC. has approximately 23.1 months of cash runway.
Who is the CEO of ARATANA THERAPEUTICS, INC.?
Information About This is the chief executive officer of ARATANA THERAPEUTICS, INC. (PETX).
Get the full picture on ARATANA THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.